Independent fund research. Built on SEC filings.

How we research funds

ETF · Large Blend · ARK Invest

Bushido Capital US Equity ETF (SMRI)

Ticker SMRI · Since 2023-09-13 · · Holdings as of Jul 31, 2026

Expense ratio
0.71%$71/yr per $10k
1-yr return
+19.1%as of Dec 2024
Net assets
$644.3Mall share classes
Holdings
51

Bottom line

Is SMRI a good fund? The bottom line

SMRI is an actively managed large blend ETF from ARK Invest.

Annual fees run 0.71% — about $71 a year on every $10,000 invested, cheaper than 60% of large blend funds we track.

It returned +19.1% over one year (as of Dec 31, 2024, per its prospectus).

With $644 million in net assets and 51 holdings, its largest position is Tenet Healthcare Corp (2.6%) and the top 10 make up 23.5% of the portfolio.

What to watch

  • High turnover (125% a year) can mean more taxable distributions

Updated Nov 19, 2026

What SMRI invests in

The Bushido Capital US Equity ETF (the Fund) seeks to provide long-term capital appreciation.

The Fund is an actively managed exchange-traded fund (ETF) that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of the Funds net assets (plus the amount of any borrowings for investment purposes) in U.S. listed common stock. The Fund is expected to generally hold 30 to 50 stocks that are equal weighted within the portfolio. The Fund utilizes a fundamental value approach to individual stock selection that incorporates both quantitative and qualitative analysis. In selecting securities for the Fund, the sub-adviser, Sepio Capital L.P. (the Sub-Adviser), primarily focuses on the amount, over a full economic cycle (typically a 3-5 year time period), of free cash flow generated by a business relative to the companys enterprise value, the return on invested capital the business generates, and the capital allocation track record of a companys…

From the fund's prospectus (filed Nov 20, 2025).

SMRI performance

Fund calendar-year total returns, 2024–2024 2024: +19.1% +19.1% 2024
Fund gain (+)
Average annual total returns
1 yr5 yr10 yr
SMRI+19.1%——
Large Blend median+13.8%+9.7%+10.9%

Source: Fund prospectus, as of Dec 31, 2024

Full SMRI performance history →

What SMRI costs

On a $10,000 investment, SMRI's 0.71% expense ratio costs about $71 a year. The prospectus estimates $883 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.

See the full SMRI fee table →

SMRI top 10 holdings

#Holding% of fund
1Tenet Healthcare Corp THC2.57%
2Workday Inc WDAY2.52%
3Accenture PLC ACN2.38%
4Valero Energy Corp VLO2.33%
5Veeva Systems Inc VEEV2.33%
6Marathon Petroleum Corp MPC2.32%
7Adobe Inc ADBE2.31%
8Phillips 66 PSX2.25%
9Intuit Inc INTU2.23%
10Expedia Group Inc EXPE2.21%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 23.5% of the fund. See all top 25 holdings and asset mix →

Alternatives to SMRI

More funds like SMRI →

SMRI FAQ

What is the expense ratio of SMRI?
SMRI's expense ratio is 0.71%, which works out to about $71 a year for every $10,000 invested. The prospectus estimates total costs of $883 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is SMRI a good investment?
It depends on your goals, but the data points to: high turnover (125% a year) can mean more taxable distributions. This is general information, not personalized advice.
What does SMRI hold?
SMRI's largest holdings are Tenet Healthcare Corp (2.6%), Workday Inc (2.5%), Accenture PLC (2.4%), Valero Energy Corp (2.3%), Veeva Systems Inc (2.3%). It holds 51 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
Who manages SMRI?
SMRI is offered by ARK Invest through EA Series Trust.